Research gap
A research opportunity connected to missing evidence, methods, datasets, validation, or translation.
Gap type
Priority
Evidence
Status
Followers
Evidence links
Preparing research brief
The platform is organizing evidence for this page. Linked papers and discussion remain available while the brief is prepared.
The first accepted evidence set for Personalized cancer vaccines includes 12 papers. Evidence currently spans 2023 to 2025. Methods represented in the accepted evidence include SHAP analysis, Survival analysis, Multi-omics analysis (TCGA data). The most specific unresolved gap is unresolved evidence gap around vaccine stability. Paper intelligence specifically flags: Vaccine stability; Global accessibility; Optimization of immune responses. This gap should be tracked as topic memory, paper intelligence, and future accepted evidence mature.
Current barriers will appear when evidence is linked or reviewed.
Multi-omics and AI-driven immune subtyping to optimize neoantigen-based vaccines for colorectal cancer
Karthick Vasudevan; T Dhanushkumar; Sripad Rama Hebbar; Prasanna Kumar Selvam; Majji Rambabu; K. Anbarasu; Rohini Karunakaran · 2025 · Scientific Reports
Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity
Ting Fan; Congcong Xu; Jichuan Wu; Yihua Cai; WuQiang Cao; Haifa Shen; Mingna Zhang; Hanfei Zhu; Jingxian Yang; Zhounan Zhu; Xiaopin Ma; Jiale Ren; Lei Huang; Qianyun Li; Yuying Tang; Bo Yu; Chunxiu Chen; Mingcheng Xu; Qiuhe Wang; Zhuya Xu; Fengjia Chen; Shujing Liang; Zhixian Zhong; Anmbreen Jamroze; Dean G. Tang; Hangwen Li; Chunyan Dong · 2024 · Science Advances
Future work suggestions will appear when the gap has enough evidence.
Possible methods or datasets
Suggest cohorts, benchmarks, validation settings, or datasets that would make this gap testable.
Translational opportunity
Connect the gap to engineering, clinical, or deployment contexts where a stronger answer would matter.
Timeline entries will appear as linked evidence accumulates.
Public discussions linked to this gap will appear here.
Suggest evidence
Add papers or datasets that demonstrate, narrow, or challenge this gap.
Suggest an update
Help refine the gap when new studies change the opportunity.
Follow updates
Save or follow this gap to track how the evidence evolves.
Signal current status
Useful contributions cite evidence, clarify uncertainty, or explain why the object has changed.
Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma
Cody A. Ramirez; Michelle Becker‐Hapak; Kartik Singhal; David A. Russler‐Germain; Felix Frenkel; Erica K. Barnell; Ethan McClain; Sweta Desai; Timothy Schappe; Onyinyechi C. Onyeador; Olga Kudryashova; Vladislav Belousov; Alexander Bagaev; Elena Ocheredko; Susanna Kiwala; Jasreet Hundal; Zachary L. Skidmore; Marcus P. Watkins; Thomas B. Mooney; Jason Walker; Kilannin Krysiak; Felicia Gomez; Catrina C. Fronick; Robert S. Fulton; Robert D. Schreiber; Neha Mehta–Shah; Amanda F. Cashen; Brad S. Kahl; Ravshan Ataullakhanov; Nancy L. Bartlett; Malachi Griffith; Obi L. Griffith; Todd A. Fehniger · 2024 · Blood Advances
Existing attempts will appear when papers are linked.
Limitations will be summarized from reviewed evidence when available.